Gestational tissue transcriptomics in term and preterm human pregnancies: a systematic review and meta-analysis

Haley R. Eidem1, William E. Ackerman IV2, Kriston L. McGary1, Patrick Abbot1 and Antonis Rokas1*

Abstract

Background: Preterm birth (PTB), or birth before 37 weeks of gestation, is the leading cause of newborn death worldwide. PTB is a critical area of scientific study not only due to its worldwide toll on human lives and economies, but also due to our limited understanding of its pathogenesis and, therefore, its prevention. This systematic review and meta-analysis synthesizes the landscape of PTB transcriptomics research to further our understanding of the genes and pathways involved in PTB subtypes.

Methods: We evaluated published genome-wide pregnancy studies across gestational tissues and pathologies, including those that focus on PTB, by performing a targeted PubMed MeSH search and systematically reviewing all relevant studies.

Results: Our search yielded 2,361 studies on gestational tissues including placenta, decidua, myometrium, maternal blood, cervix, fetal membranes (chorion and amnion), umbilical cord, fetal blood, and basal plate. Selecting only those original research studies that measured transcription on a genome-wide scale and reported lists of expressed genetic elements identified 93 gene expression, 21 microRNA, and 20 methylation studies. Although 30% of all PTB cases are due to medical indications, 76% of the preterm studies focused on them. In contrast, only 18% of the preterm studies focused on spontaneous onset of labor, which is responsible for 45% of all PTB cases. Furthermore, only 23 of the 10,993 unique genetic elements reported to be transcriptionally active were recovered 10 or more times in these 134 studies. Meta-analysis of the 93 gene expression studies across 9 distinct gestational tissues and 29 clinical phenotypes showed limited overlap of genes identified as differentially expressed across studies.

Conclusions: Overall, profiles of differentially expressed genes were highly heterogeneous both between as well as within clinical subtypes and tissues as well as between studies of the same clinical subtype and tissue. These results suggest that large gaps still exist in the transcriptomic study of specific clinical subtypes as well in the generation of the transcriptional profile of well-studied clinical subtypes; understanding the complex landscape of prematurity will require large-scale, systematic genome-wide analyses of human gestational tissues on both understudied and well-studied subtypes alike.

Keywords: Preterm birth, Gestational tissues, Transcriptomics, Gene expression, microRNA, Methylation, Preeclampsia, Idiopathic preterm birth, Meta-analysis

* Correspondence: antonis.rokas@vanderbilt.edu
1 Department of Biological Sciences, Vanderbilt University, VU Station B #35-1634, Nashville, TN 37235, USA
Full list of author information is available at the end of the article

© 2015 Eidem et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

In humans, gestation typically lasts 40 weeks; preterm birth (PTB) is defined as birth before 37 completed weeks of gestation and is the leading cause of newborn death worldwide. More than 15 million babies are born too soon every year and rates of PTB had been increasing until 2006 when changes in obstetrical practices regarding early cesarean sections led to a recent decrease in deliveries before term [1]. Nevertheless, 10 % of pregnancies still end before 37 weeks across the world and this high incidence of PTB is problematic because premature babies are at higher risk for lifelong health and developmental problems [2, 3]. For example, almost half of all children born premature suffer from vision or hearing loss and learning disabilities at some point in their life [4, 5]. The combined medical costs stemming from care during the labor and delivery process as well as from care later in life are estimated to be near $26 billion annually [6].

PTB is a complex, multifactorial syndrome comprised of multiple clinical subtypes, which often occur at different gestational ages and can be defined as either ‘spontaneous’ or ‘medically indicated’ [7]. Medically indicated preterm deliveries account for 30 % of PTB cases and are often preceded by complications including preeclampsia (PE), intrauterine growth restriction (IUGR), gestational diabetes mellitus (GDM), and chorioamnionitis [8]. The remaining 70 % of PTB cases are idiopathic; 45 % is due to the spontaneous onset of labor (sPTB) and the remaining 25 % is due to the preterm premature rupture of membranes (PPROM) [9–11]. Regardless of PTB subtype, however, current therapies are not successful in prolonging time to birth once labor has been initiated and the most effective therapy, progesterone supplementation, is only effective in a small number of high-risk cases [12].

It is critical that we gain greater insight into the genes and pathways that regulate birth timing in humans in order to develop effective prevention and treatment strategies, including for cases of sPTB.

A number of environmental risk factors have been associated with sPTB including infection, nutrition, socioeconomic status, and stress but the pathways through which these risk factors act remain unclear [13]. Recent evidence from family, twin, and case–control studies suggests that genetics also plays an important role in birth timing, and the heritability of PTB is estimated to be approximately 30 % [1, 6, 8]. Thus, PTB tends to run in families and women who were born preterm are also more likely to deliver preterm themselves. Interestingly, however, fathers born prematurely do not appear to pass on this risk to offspring [1].

Furthermore, one of the strongest predictors of PTB is previous preterm birth and, in subsequent pregnancies from the same woman, birth timing tends to occur around the same gestational age for each pregnancy [9, 14]. Candidate gene studies have targeted genes with known biological roles potentially related to processes occurring during pregnancy but, in general, teasing apart the complex genetic architecture of pregnancy and PTB has proved challenging.

Further complicating our understanding of PTB genetic architecture are the numerous maternal and fetal gestational tissues that must interact to facilitate parturition [12, 15]. These tissues include decidua, myometrium, cervix and maternal blood originating from the mother and villous placenta, fetal membranes (chorion and amnion), umbilical cord, and fetal blood originating from the fetus (Fig. 1). Furthermore, the basal plate is a region at the maternofetal interface that is commonly biopsied for the study of PTB and includes cells from both the decidua and villous placenta. The decidua, myometrium, and cervix act to house the fetus as well as expel it during labor and delivery, the chorion and amnion act as membranes separating the fetus from the mother, and the umbilical cord allows for efficient nutrient transfer. Together, these tissues share a general functionality in the efficient maternofetal exchange of nutrients, gas, and waste.

Although little is known about the complex etiology of PTB, many studies have generated pregnancy-related transcriptomes in various tissue types and pathologies. Because of the diversity of tissues and clinical subtypes involved as well as the large number of questions examined, few studies have attempted to synthesize any dimension of the admittedly complex transcriptional landscape of this multifactorial syndrome. To synthesize...
what is known about PTB transcriptomics, we analyzed all published genome-wide studies of gestational tissues (placenta, decidua, myometrium, maternal blood, cervix, basal plate, fetal membranes, umbilical cord, and fetal blood) in both healthy and diseased human pregnancies to identify all statistically supported candidate genetic elements in PTB subtypes.

Our meta-analysis identified 134 genome-wide studies of pregnancy and PTB. The majority of PTB research focused on PE; very few studies were focused on sPTB (18 %) even though sPTB accounts for 45 % of all PTB cases. Moreover, there was limited overlap in the identity of candidate genes across studies. In placenta (n = 53), for example, 6,444 differentially expressed unique genes were identified but only 2, LEP and FLT1, were present in more than 10 gene expression studies. Similarly, in PE studies (n = 27), 5,329 differentially expressed unique genes were identified but only 13 were found in 5 or more gene expression studies. The limited overlap of differentially expressed genes across studies of the same tissue or clinical subtype as well as the highly uneven coverage of studies targeting highly prevalent clinical subtypes suggest that larger-scale, systematic studies aimed at understanding the transcriptional profiles of the diverse clinical PTB subtypes and characterizing their disease-relevant transcriptional differences will be necessary to identify genes whose dysregulation contributes to this complex, multifactorial syndrome.

Results
A systematic review identified 134 transcriptomic studies on 9 gestational tissues and 29 different phenotypes
Of the 2,361 studies identified in our PubMed search, 134 genome-wide transcriptomic studies in human gestational tissue samples were, based on a number of selection criteria, deemed eligible for systematic review (Additional file 1) [16–133]. These 134 studies were identified from a total of 116 distinct publications; this is so because 14 publications reported multiple comparisons that were separated into 33 distinct studies for the purpose of this analysis. Platform-wise, 127/134 (95 %) were microarray studies, 4/134 (3 %) were bisulfite-sequencing studies, and 3/134 (2 %) were RNA-sequencing studies. All studies were published between 1999 and 2014, primarily in the journals *Placenta* and *The American Journal of Obstetrics and Gynecology*. The phenotypes examined in these studies were quite diverse; 14/134 (10 %) studies examined preterm pregnancies, 80/134 (60 %) term pregnancies, and 40/134 (30 %) both preterm and term pregnancies. One non-clinical phenotype (healthy pregnancies) and 28 distinct clinical phenotypes were represented. Finally, 21/134 (16 %) were microRNA studies, 20/134 (15 %) were methylation studies, and the remaining 93/134 (69 %) were gene expression studies. A total of 10,993 unique genetic elements were reported to be transcriptionally active across all 134 studies (Additional file 2), but only 23/10,993 (0.2 %) were reported in 10 or more studies.

The 134 studies analyzed 9 distinct gestational tissues, namely placenta, decidua, myometrium, maternal blood, cervix, fetal membranes (chorion and amnion), umbilical cord, fetal blood, and basal plate. The three most common tissues studied were placenta (82/134; 61 %), fetal membranes (16/134; 12 %), and myometrium (17/134; 12 %), whereas each of the other six tissues was sampled in 7 or fewer studies (Fig. 2).

The 134 studies analyzed 29 distinct phenotypes (Fig. 3). 11/134 (8 %) studies focused on healthy pregnancies, while the remaining 123/134 (92 %) studies focused on clinical phenotypes. The most common phenotypes studied were PE (40/134; 30 %), labor (16/134; 12 %), and sPTB (10/134; 7 %). Definitions for all phenotypes are provided in Additional file 3.

PTB research focus does not reflect PTB subtype epidemiological prevalence
To evaluate whether the proportion of transcriptomic studies devoted on different PTB subtypes reflects their clinical prevalence, we compared the frequencies of the three major clinical etiologies (sPTB at 45 %, PPROM at 25 %, and medically indicated PTB at 30 %) to the frequency of transcriptomic studies devoted to these etiologies (Fig. 4). We found that although only 30 % of all PTB cases are due to medical indications, such as PE, IUGR, or GDM, 41/54 (76 %) of the studies categorized as preterm in our systematic review focused on them; 21/54 (39 %) of the preterm studies focused on PE alone. In contrast, although sPTB is responsible for 45 % of all cases, only 10/54 (18 %) of the preterm studies in our systematic review studied this clinical subtype.

A meta-analysis of 93 gene expression studies across 9 distinct gestational tissues showed limited overlap of candidate genes
To perform an aggregated meta-analysis, we focused on the 93/134 gene expression studies. These 93 gene expression studies analyzed all 9 distinct gestational tissues, namely placenta, decidua, myometrium, maternal blood, cervix, fetal membranes (chorion and amnion), umbilical cord, fetal blood, and basal plate. The three most common tissues studied for differential gene expression were placenta (53/93; 57 %), myometrium (17/93; 18 %), and fetal membranes (11/93; 12 %), whereas each of the other six tissues was sampled in 4 or fewer studies. Genome-wide gene expression profiling studies of the three most commonly studied gestational tissues, i.e., placenta, myometrium, and fetal membranes, identified a total of 8,437 unique differentially expressed genes, of
which only 2,123 (25%) were found in two or more studies (Fig. 5, Additional file 4). This examination also showed that only 23 candidate genes were differentially expressed two or more times in studies of all three tissues (Additional file 5). Among the genes present in this overlap were interleukin 1 beta, a proinflammatory cytokine shown to be involved in infection-related PTB and PE, and superoxide dismutase 2, an antioxidant enzyme shown to be involved in oxidative stress associated with PTB [18, 23, 34, 49, 65, 134–138].

Although gene expression profiles are available for 29 distinct phenotypes, PTB research is dominated by studies focused on select phenotypes of PTB. The 93 gene expression studies analyzed 29 distinct phenotypes. From these studies, 5/93 (5%) focused on a...
non-clinical phenotype (healthy pregnancies), with the remaining 88/93 (95%) focused on clinical phenotypes. Among studies focused on clinical phenotypes, the three most common phenotypes investigated were PE (27/93; 29%), labor (15/93; 16%), and IUGR (8/93; 9%); each of the other 26 clinical phenotypes was studied in 5 or fewer studies. Genome-wide gene expression studies of the three most commonly studied clinical phenotypes identified a total of 7,730 unique genes, of which only 1,336 (15%) were present in two or more studies (Fig. 6, Additional file 6). No candidate genes were found two or more times in studies of all three phenotypes. Generally, overlap of

![Fig. 4 Proportion of transcriptomic research does not correspond to PTB subtype prevalence. Although only 30% of all PTB cases are due to medical indications, such as PE, IUGR, or GDM, 76% of the preterm studies in our systematic review focused on them. In contrast, only 18% of the studies focused on sPTB, even though this clinical subtype accounts for the majority (45%) of PTB cases.](image1)

![Fig. 5 Overlap of differentially expressed genes across tissues. Differentially expressed genes present in two or more gene expression studies categorized by tissue were compared across the three most commonly studied (placenta, myometrium, and fetal membranes). Out of 2,123 genes identified to be differentially expressed in at least two studies, 23 genes were shared across all three tissues.](image2)

![Fig. 6 Overlap of differentially expressed genes across phenotypes. Differentially expressed genes identified in two or more gene expression studies categorized by phenotype were compared across the most commonly studied (PE, labor, and IUGR). Out of 1,336 genes identified to be differentially expressed in at least two studies, none were shared across all three phenotypes.](image3)
differentially expressed genes was more limited across clinical phenotypes than across gestational tissues.

**Overlap of differentially expressed genes identified across PTB studies is limited**

Studies of placenta, myometrium, and fetal membranes, the three most commonly studied tissues, focused on a total of 25 distinct phenotypes (Fig. 7a, Additional file 7). The clinical phenotype studied, however, differed between tissues, with PE dominating placental research (23/53 placental studies or 43%), labor dominating myometrial research (9/17 myometrial studies or 53%), and PPROM dominating fetal membrane research (4/13 fetal membrane studies or 31%). Likewise, the range of tissues studied differed between phenotypes. PE was studied across 4 distinct gestational tissues (placenta, decidua, basal plate, and maternal blood), labor was studied across 4 distinct gestational tissues (myometrium, fetal membranes, placenta, and cervix), and PPROM was studied across only 1 distinct gestational tissue (fetal membranes) (Fig. 7b, Additional file 8).

To identify common differential gene expression signatures, we looked for overlap between differentially expressed genes identified across PTB studies. Studies are represented as distinct wedges in the outermost track, colored by phenotype and sized by number of genes reported. Genes that show a high degree of overlap across studies (4 or more placenta, PE, or PE in placenta studies; 4 or more myometrium, labor, or labor in myometrium studies; 4 or more fetal membranes studies; or 2 or more PPROM or PPROM in fetal membranes studies) appear as black links connecting each study reporting the gene. In general, the scarcity of links illustrates the considerable lack of overlap in the genes identified as differentially expressed across PTB studies.

**Fig. 7** Representation of overlap in differentially expressed genes across the most commonly studied tissues, phenotypes, and tissues & phenotypes. Studies are represented as distinct wedges in the outermost track, colored by phenotype and sized by number of genes reported. Genes that show a high degree of overlap across studies (4 or more placenta, PE, or PE in placenta studies; 4 or more myometrium, labor, or labor in myometrium studies; 4 or more fetal membranes studies; or 2 or more PPROM or PPROM in fetal membranes studies) appear as black links connecting each study reporting the gene. In general, the scarcity of links illustrates the considerable lack of overlap in the genes identified as differentially expressed across PTB studies. a) Representation of overlap in differentially expressed genes across the most commonly studied tissues. Studies of placenta, myometrium, and fetal membranes, the three most commonly studied tissues, focused on a total of 25 distinct phenotypes with PE dominating placental research, labor dominating myometrial research, and PPROM dominating fetal membranes research. b) Representation of overlap in differentially expressed genes across the most commonly studied phenotypes. PE was studied across 4 distinct gestational tissues (placenta, decidua, basal plate, and maternal blood), labor was studied across 4 distinct gestational tissues (myometrium, fetal membranes, placenta, and cervix), and PPROM was studied across only 1 distinct gestational tissue (fetal membranes). c) Representation of overlap in differentially expressed genes across the most commonly studied tissue and phenotype combinations. The most studied combinations were PE in placenta (n = 23), labor in myometrium (n = 9), and PPROM in fetal membranes (n = 3). Examination of PE in placenta studies identified 16 genes that were present in 4 or more studies, examination of labor in myometrium studies identified 15 genes that were present in 4 or more studies, and examination of PPROM in fetal membranes studies identified 6 genes that were present in 2 or more studies.
expressed genes reported in studies of the same phenotype and tissue. The most studied phenotype-tissue combinations were PE in placenta (n = 23), labor in myometrium (n = 9), and PPROM in fetal membranes (n = 4) (Fig. 7c, Table 1). Examination of PE in placenta studies identified 16 genes that were present in 4 or more studies including 

**LEP**, a fat-regulating hormone commonly shown to be differentially expressed in gestational tissues of women with PE and HELLP Syndrome, and **FLT1**, a growth factor known to be highly expressed in pre-eclamptic placental trophoblast cells [21, 32, 44, 48, 53, 75, 80, 88, 94]. Examination of labor in myometrium studies identified 15 genes that were present in 4 or more studies including **PTGS2**, a cyclooxygenase involved in inflammation and commonly upregulated in myometrium during labor [18, 26, 40, 64, 66, 136, 139]. Finally, 6 genes were present in 2 or more PPROM in fetal membranes studies including **IL8**, a proinflammatory chemokine often associated with PTB [36, 37, 55, 87, 92, 140].

To examine whether the sets of genes that were most prevalent in each of the three tissue and phenotype pairs (PE in placenta, labor in myometrium, and PPROM in fetal membranes) disproportionally represented particular functions, we examined whether any Gene Ontology functional category was statistically significantly enriched (p < 0.0001) in each of the three gene sets (Additional file 9). Candidate genes identified in PE in placenta studies were enriched for regulation of cell death (GO:0010941) and apoptosis (GO:0042981), candidate genes identified in labor in myometrium were enriched for wounding (GO:0009611) and inflammatory response (GO:0006954), and candidate genes identified in PPROM in fetal membranes were enriched for immune system process (GO:0002376) and immune response (GO:0006955).

**Discussion**

PTB is a complex, multifactorial syndrome with high prevalence worldwide, whose pathogenesis remains poorly understood, especially for cases of early spontaneous labor. To provide an overview as well as a synthesis of the current landscape of PTB transcriptomics, we conducted an in-depth systematic review of the literature as well as a meta-analysis of 93 gene expression studies on a wide diversity of gestational tissues and clinical phenotypes. Examination of our results identifies two key findings. First, the correspondence between PTB subtype prevalence and proportion of transcriptomic research devoted to these subtypes is weak. Second, the overlap between differentially expressed genes identified in different studies is quite small, even on studies aimed on the same phenotypes and tissues. Below, we discuss the possible factors that underlie these two key findings and their implications for research on PTB.
In general, transcriptomic studies on placental tissue samples from women with preeclampsia dominate PTB research. Furthermore, there are very few studies focusing on sPTB, a subtype responsible for 45% of all PTB cases. Although genes commonly associated with PTB clinical subtypes (i.e., LEP and FLT1) are identified in many of the gene expression studies to be differentially expressed, the overlap between the differentially expressed genes identified across studies is generally very limited. This is not surprising in comparisons between tissues (Fig. 5) because these often involve examinations of different clinical subtypes, although it does suggest that there is little overlap in tissue-specific transcriptional profiles of different clinical subtypes. Similarly, it is not surprising that comparisons between clinical subtypes do not show a high degree of overlap (Fig. 6) because these often involve examinations of different tissues. Nevertheless, it should be noted that differentially expressed genes with substantial overlap across studies appear to be biologically meaningful. For example, genes involved in hormone regulation (i.e., CGB, CRH, INHA, and GH2), which have been previously shown to be key in the maintenance of pregnancy, show substantial overlap in preeclampsia studies. Genes involved in inflammation (i.e., IL8), which have been previously shown to be dysregulated in PPROM and other clinical PTB subtypes, are also identified to be differentially expressed in multiple studies.

The observed minimal overlap between the differentially expressed genes identified across studies focused on the same tissue and clinical phenotype (Fig. 7) is possibly more serious. One potential explanation may be the difficulty in obtaining appropriate controls important in pregnancy research; comparing studies that differ with respect to the presence of labor, gestational age, and fetal sex is challenging, since all of these factors are thought to influence the gene expression landscape in gestational tissues. Even though matching of samples with respect to all these factors is very challenging, the reporting of a standard list of such factors as required metadata in transcriptomic studies would facilitate further examination of their importance and likely influence on transcriptomic profiles.

In addition to transcriptomics, several other systematic reviews and meta-analyses have focused on identifying biomarkers, usually proteins, that are associated with PTB [141–143]. Overlapping 19 previously identified common PTB biomarkers with the studies in our meta-analysis indicates that most (12/19; 63%) are replicated in 4 or more studies (Table 2). Therefore, our comparison shows evidence of considerable overlap between transcriptomic and proteomic studies in PTB. Further research from both approaches is necessary, however, because our comparison also indicates that transcriptomics and proteomics can target unique candidate genes and proteins as well.

Furthermore, the recent publication of comprehensive phenotyping tools necessitates the connection of evidence-based phenotype knowledge with genomic data collection in order to make more targeted conclusions [144]. It’s challenging to compare and contrast gene expression signatures between distinct subtypes without knowing whether the transcriptomes came from cases of sPTB due to maternal stress, uterine distention, or another subtype. Therefore, a greater focus needs to be placed on collecting the most detailed meta-data available regarding sPTB diagnosis as well as performing genome-wide studies of these newly described sPTB subtypes.

Finally, it is important to note that different studies follow different guidelines with respect to data availability. For example, some studies do not report the full list of differentially expressed genes identified or do not make them easily available for subsequent analysis (e.g., reporting tables that contain differential expression data on hundreds or thousands of genes in PDF format), therefore limiting and biasing the data available for subsequent analyses. The publishing of the data for all genes with differential expression above an explicit significance threshold in an easily accessible format is crucial in order to carefully analyze aggregated results and draw meaningful conclusions.

| Entrez gene ID | Official gene symbol | # studies |
|---------------|---------------------|-----------|
| 1392          | CRH                 | 11        |
| 6279          | S100A8              | 10        |
| 3569          | IL6                 | 9         |
| 1082          | CGB                 | 9         |
| 2335          | FN1                 | 9         |
| 3553          | IL1B                | 9         |
| 7124          | TNF                 | 6         |
| 5617          | PRL                 | 5         |
| 2810          | SFN                 | 4         |
| 6283          | S100A12             | 4         |
| 2512          | FTL                 | 4         |
| 4318          | MMP9                | 4         |
| 5443          | POMC                | 2         |
| 174           | AFP                 | 1         |
| 4317          | MMP8                | 0         |
| 308           | ANXA5               | 0         |
| 3700          | ITIH4               | 0         |
| 3558          | IL2                 | 0         |
| 6013          | RLN1                | 0         |
Conclusions
This study synthesizes all high-quality transcriptomic studies on gestational tissues to examine the landscape of PTB as well as to identify genes and genomic elements associated with it. We found that highly prevalent PTB subtypes, such as sPTB, are not well studied and that differentially expressed genes identified in different studies are often non-overlapping. Thus, the identification of the genes whose dysregulation contributes to this complex and multifactorial syndrome will require many more large-scale, systematic studies aimed at understanding the transcriptional profiles of these diverse clinical PTB subtypes across gestational tissues and characterizing their disease-relevant transcriptional differences.

Note Added in Proof
While this manuscript was in review, by studying the variation in the placental transcriptome of healthy humans, Hughes and coworkers estimated that more than 90 % of the observed transcriptomic variation is explained by variation within and between individuals [145]. These results provide an alternative, yet complementary, explanation for our finding that profiles of differentially expressed genes were highly heterogeneous both between and within clinical subtypes and tissues as well as between studies of the same clinical subtype and tissue.

Methods
Search strategy
This systematic review and meta-analysis followed guidelines set by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (Additional files 10, 11 and 12) [146]. The electronic search was performed on August 16, 2014 in PubMed with no restrictions to identify all articles relating to differentially expressed or methylated genes and microRNAs in human gestational tissues. The search strategy was constructed based on related MeSH terms:

"Pregnancy"[mh] AND "Humans"[mh] AND ("Gene Expression Profiling"[mh] OR "Gene Expression Regulation"[mh]) AND ("Placenta"[mh] OR "Decidua"[mh] OR "Myometrium"[mh] OR "Cervix Uteri"[mh] OR "Extraembryonic Membranes"[mh] OR "Blood"[mh] OR "Plasma"[mh] OR "Umbilical Cord"[mh])

Systematic review
We collected abstracts for all 2,361 studies identified from this search and annotated eligibility based on 6 inclusion criteria:

1. Published in English
2. Full text available
3. Original research
4. Human gestational tissue samples
5. Genome-wide analysis
6. Candidate gene list assembled

134 studies met all 6 criteria and were included in the systematic review. Furthermore, studies were excluded when the study data was not accessible (the number of gene candidates was reported but the list of candidate genes was not), the study data was not reported (the number of candidate genes was not reported and a list of candidate genes was not provided), the data was unclear, there were no significant gene candidates, the study was not genome-wide, the study was not human-specific, the study was not relevant, the study was not single-gene based (i.e., was focused on pathways or gene sets), the study used data from proteomics, the study was performed on cell line rather than in an in-vivo tissue, the study's supplement was not available, or when the study's tissue was collected before the third trimester (Additional file 12).

Meta-analysis
Studies were included in our meta-analysis if they met an additional 3 inclusion criteria:

1. Studied differential gene expression
2. Provided candidate gene list
3. DAVID ID conversion successful

116 references met all inclusion criteria and, due to multiple comparisons or analyses in 14 of these references, a total of 134 distinct studies were summarized (Additional file 1). Of the 134 studies included in our systematic literature review, 93 gene expression studies met these criteria and were further analyzed. All differentially expressed genes reported in these studies were first extracted and then converted to Entrez ID format using the DAVID online tool, selecting the smallest Entrez ID number if multiple IDs mapped to single genes. We extracted all reported significantly differentially expressed genes based on each study's significance threshold for differential expression. Overlap was determined simply by the presence of the same gene in the gene lists from different studies. DAVID was used to assay functional enrichment according to Gene Ontology categories. All analyses were performed using Python and visualizations were performed using ggplot2 and Circos [147, 148].

Additional files

Additional file 1: Summary of studies in systematic review.
Additional file 2: All reported candidate genomic elements.

Additional file 3: Phenotype definitions.

Additional file 4: Duplicated genes in well-studied gestational tissues. Genes in 2 or more placenta studies or 2 or more myometrium studies or 2 or more fetal membranes studies.

Additional file 5: Well-replicated genes in well-studied gestational tissues. 12 genes in 2 or more placenta studies and 2 or more myometrium studies and 2 or more fetal membranes studies.

Additional file 6: Duplicated genes in well-studied clinical phenotypes. Genes in 2 or more PE studies or 2 or more labor studies or 2 or more IUGR studies.

Additional file 7: Well-replicated genes in placenta, myometrium, and fetal membranes. Genes in 5 or more placenta studies or 5 or more myometrium studies or 5 or more fetal membranes studies.

Additional file 8: Well-replicated genes in PE, labor, and PPROM. Genes in 5 or more PE studies or 5 or more labor studies or 2 or more PPROM studies.

Additional file 9: GO enrichment. Enriched GO functional categories for replicated genes in PE in placenta, labor in myometrium, and PPROM in fetal membranes.

Additional file 10: PRISMA checklist.

Additional file 11: PRISMA flow chart.

Additional file 12: Excluded studies. All studies excluded from systematic review.

Abbreviations
PTB: Preterm birth; sPTB: Spontaneous idiopathic preterm birth; PE: Preeclampsia; IUGR: Intrauterine growth restriction; GDM: Gestational diabetes mellitus; PPROM: Preterm premature rupture of membranes; MeSH: medical subject headings.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
HRE and AR designed the study with input from WEA, KLM, and PA. HRE carried out the study and drafted the manuscript with subsequent contributions and revisions from AR. All authors read and approved the final manuscript.

Acknowledgements
We thank Louis J. Muglia for offering invaluable advice on experimental design at an early stage of this experiment. This work was conducted in part using the resources of the Advanced Computing Center for Research and Education at Vanderbilt University. HRE was supported by the Graduate Program in Biological Sciences at Vanderbilt University. Research on this project was supported by the March of Dimes through the March of Dimes Prematurity Research Center Ohio Collaborative.

Author details
1 Department of Biological Sciences, Vanderbilt University, VU Station B #35-1634, Nashville, TN 37235, USA. 2 Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH 43210, USA.

Received: 19 December 2014 Accepted: 12 May 2015
Published online: 05 June 2015

References
1. Muglia LJ, Katz M. The enigma of spontaneous preterm birth. N Engl J Med. 2010;362:529–35.
2. Blencowe H, Couzens S, Ostergaard MZ, Chou D, Moller AB, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. The Lancet. 2012;379:2162–72.
3. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2006;371:75–84.
4. Esplin MS. Overview of spontaneous preterm birth: a complex and multifactorial phenotype. Clin Obstet Gynecol. 2014;57:518–30.
5. Chang HH, Larson J, Blencowe H, Hsiao CY, Howson CP, Cairns-Smith S, et al. Preventing preterm births: analysis of trends and potential reductions with interventions in 39 countries with very high human development index. The Lancet. 2013;381:223–34.
6. Plunkett J, Muglia LJ. Genetic contributions to preterm birth: implications from epidemiological and genetic association studies. Ann Med. 2008;40:167–95.
7. Myatt L, Eschenbach DA, Lye SJ, Mesiano S, Muthua AP, Williams SM, et al. A standardized template for clinical studies in preterm births. Reprod Sci. 2012;19:747–82.
8. Menon R. Spontaneous preterm birth: a clinical dilemma etiologic, pathophysiology and genetic heterogeneities and racial disparity. Acta Obstet Gynecol Scand. 2008;87:590–600.
9. Ananth CV, Vintzileos AM. Epidemiology of preterm birth and its clinical subtypes. J Matern-Fetal Neonatal Med Off J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet. 2006;19:773–82.
10. Henderson JJ, McWilliam OA, Newnham JP, Pennell CE. Preterm birth anteclene 2004–2008: Maternal factors associated with three phenotypes: spontaneous preterm labour, preterm pre-labour rupture of membranes and medically indicated preterm birth. J Matern Fetal Neonatal Med. 2012;25:642–7.
11. Moutquin J. Classification and heterogeneity of preterm birth. BJOG Int J Obstet Gynaecol. 2003;110:30–3.
12. Romero R, Dey SK, Fisher SJ. Preterm labor: one syndrome, many causes. Science. 2014;345:760–5.
13. Bezdol IY, Karjalainen MK, Hallman M, Teramo K, Muglia LJ. The genomics of preterm birth: from animal models to human studies. Genome Med. 2013;5:34.
14. Lengyl C, Muglia LJ, Pavlicev M. Genetics of Preterm Birth. eLS. 2014:1–3.
15. Iams JD. Preterm birth categories-labels with consequences. Ann J Obstet Gynecol. 2014;210:978–82.
16. Arcelli D, Farina A, Cappuzzello C, Bresin A, De Sanctis P, Perolo A, Pandrasteller D, Valantini D, Zucchini C, Priori S, Rizzo N: Identification of circulating placental mRNA in maternal blood of pregnancies affected with fetal congenital heart diseases at the second trimester of pregnancy: implications for early molecular screening. Prenat Diagn. 2010;30(9):229–34.
17. Bethin KE, Nagai Y, Sladek R, Asada M, Sadowsky Y, Hudson TJ, et al. Microarray analysis of uterine gene expression in mouse and human pregnancy. Mol Endocrinol Baltim Md. 2003;17:1454–69.
18. Bollapragada S, Bollapragada S, Yousef R, Jordan F, Greer I, Norman J, et al. Term labor is associated with a core inflammatory response in human fetal membranes, myometrium, and cervix: Am J Obstet Gynecol. 2009;200:104.e1–11.
19. Brennan DJ, McGee SF, Rexhepaj E, O’Connor PM, Robson M, O’Herlihy C. Identification of a myometrial molecular profile for dystocic labor. BMC Pregnancy Childbirth. 2011;11:74.
20. Bruchova H, Vaskova A, Merkerova M, Mikova V. Effect of maternal tobacco smoke exposure on the placental transcriptome. Placenta. 2010;31(3):186–91.
21. Buimer M, Keijser R, Jubbink JM, Wehkamp D, van Kampen AHC, Boer K, et al. Seven placental transcripts characterize HELLP-syndrome. Placenta. 2008;29:4444–53.
22. Bukowski R, Hankins GDV, Saade GR, Anderson GO, Thornton S. Labor-associated gene expression in the human uterine fundus, lower segment, and cervix. PLoS Med. 2006;3:e169.
23. Centlow M, Wingren C, Borrebaeck C, Brownstein MJ, Hansson SR. Differential gene expression analysis of placentalis with increased vascular resistance and pre-eclampsia using whole-genome microarrays. J Pregnancy. 2011;2011:472354–12.
24. Chaemsaithong P, Maden I, Romero R, Than NG, Tarca AL, Draghici S, et al. Characterization of the myometrial transcriptome in women with an arrest of dilatation during labor. J Perinat Med. 2013;41:665–81.
25. Chan EC, Fraser S, Yin S, Yeo G, Kwek K, Fairclough RJ, et al. Human myometrial genes are differentially expressed in labor: a suppression subtractive hybridization study. J Clin Endocrinol Metab. 2002;87:2435–41.
26. Chan Y-W, van den Berg HA, Moore JD, Quenby S, Blanks AM. Assessment of myometrial transcriptome changes associated with spontaneous human labour by high throughput RNA-seq. Exp Physiol. 2014;60:1–15.
27. Chang S-D, Chao A-S, Peng H-H, Chang Y-L, Wang C-N, Cheng P-J, et al. Analyses of placental gene expression in pregnancy-related hypertensive disorders. Taiwan J Obstet Gynecol. 2011;50:283–91.
28. Charpin G, Leroy M-J, Breuiller-Fouché M, Tanzin F, Mhamdy-Kodja S, Robin P, et al. A functional genomic study to identify differential gene expression in the preterm and term human myometrium. Biol Reprod. 2003;68:2896–95.
29. Chin SSC, Lee WS, Ting YH, Chan OK, Lee SWY, Leung SY. Systematic identification of spontaneous preterm birth-associated RNA transcripts in maternal plasma. PLoS ONE. 2012;7:e34328.
30. Condeaux Y, Tattelmann M, Charnock-Jones DS, Smith GC. Effects of medroxyprogesterone acetate on gene expression in myometrial explants from pregnant women. J Clin Endocrinol Metab. 2010;95:E437–47.
31. Dunk CE, Rognsossam AM, Cox B, Perkins JE, Aksenius F, Keating S, et al. A distinct microvascular endothelial gene expression pro. Placenta. 2012;33:285–93.
32. Enquobahrie DA, Meller M, Rice K, Piasty BM, Siscovick DS, Williams MA. Differential placental gene expression in preeclampsia. Am J Obstet Gynecol. 2008;199:556–15.
33. Enquobahrie DA, Williams MA, Qiu C, Meller M, Sorensen TK. Global placental gene expression in gestational diabetes mellitus. Am J Obstet Gynecol. 2009;200:206:e1–13.
34. Esplin MS, Fausett MB, Peltier MR, Hamblin S, Silver RM, Branch DW, et al. The use of cDNA microarray to identify differentially expressed labor-associated genes within the human myometrium during labor. Am J Obstet Gynecol. 2005;193:604–13.
35. Gack S, Marme A, Marme F, Wrobel G, Vonderstrass B, Bastert G, et al. Preeclampsia: increased expression of soluble ADAM 12. J Mol Med Berl Ger. 2005;83:887–96.
36. Haddad R, Tromp G, Kuivaniemi H. Human spontaneous labor without histologic chorioamnionitis is characterized by an acute inflammation gene expression signature. Am J Obstet Gynecol. 2006;195:394–405. e12.
37. Han YM, Romero R, Kim J-S, Tarca AL, Kim SK, Draghici S, et al. Region-specific gene expression profiling: novel evidence for biological heterogeneity of the human amnion. Biol Reprod. 2008;79:954–61.
38. Hansson SR, Chen Y, Brodszki J, Chen M, Hernandez-Andrade E, Inman JM, et al. Gene expression profiling of human placentas from preeclampsia and normotensive pregnancies. Mol Hum Reprod. 2006;12:169–79.
39. Hassan SS, Romero R, Tarca AL, Nhan-Chang C-L, Vaisbuch E, Erez O, et al. The transcriptome of cervical ripening in human pregnancy. Placenta. 2009;30:1060–7.
40. Herttuala S. Tumor suppressor and growth regulatory genes are overexpressed in HELLP syndrome placentas. Reprod Sci. 2008;15:285.
41. Hoegh AM, Borup R, Nielsen FC, Sørensen S, Hviid TVF. Gene expression landscape of the human placenta. BMC Genomics. 2012;13:115.
42. Lapaire O, Grill S, Laleuze S, Kolla V, Hödi I, Hahn S. Microarray screening for novel preeclampsia biomarker candidates. Fetal Diagn Ther. 2013;31:147–53.
43. Lee GSR, Joe YS, Kim SJ, Shin JC. Cytokine-related genes and oxidation-related genes detected in preeclamptic placentas. Arch Gynecol Obstet. 2010;282:363–9.
44. Lee J, Romero R, Chaiworapongs A, Tong Z, Tarca AL, Xu Y, et al. Characterization of the fetal blood transcriptome and proteome in maternal anti-fetal rejection: evidence of a distinct and novel type of human fetal systemic inflammatory response. Am J Reprod Immunol. 2013;70:265–84.
45. Li R, Ackerman WE, Summerfield TL, Yu L, Gulati P, Zhang J, et al. Inflammatory gene regulatory networks in amnion cells following cytokine stimulation: translational systems approach to modeling human parturition. PLoS ONE. 2011;6:e20569.
46. Liu IA, Toft JH, Olsen GD, Langaas M, Bjaeb L, Eide I, et al. Matrix metalloproteinase 1 in pre-eclampsia and fetal growth restriction: reduced gene expression in decidua tissue and protein expression in extravillous trophoblasts. Placenta. 2010;31:615–20.
47. Lin S, Madhyte DA, Lee YS, Khandji S, Tenzidou V, Teoh TG, et al. Nuclear factor kappa B activation occurs in the amnion prior to labour onset and modulates the expression of numerous labour associated genes. PLoS ONE. 2012;7:e34707.
48. Kang JH, Song H, Yoon JA, Park DY, Kim SH, Lee KJ, et al. Preeclampsia leads to dysregulation of various signaling pathways in placenta. J Hypertens. 2011;29:928–36.
49. Khanjani S, Kandel DA, Lindstrom TM, Soomarana SR, Melchionda M, Lee YS, et al. NF-κB regulates a casette of immune/inflammatory genes in human pregnant myometrium at term. J Cell Mol Med. 2011;15:809–24.
50. Kim MJ, Romero R, Kim J-S, Tarca AL, Chaiworapongs A, Villitis of unknown etiology is associated with a distinct pattern of Chemokine Up-regulation in the feto-maternal and placental compartments: implications for conjoint maternal allograft rejection and maternal anti-fetal graft-versus-host disease. J Immunol. 2009;182:3919–27.
51. Kim J, Zhao K, Jiang P, Lu Z, Wang J, Murray JC, et al. Transcriptome characterization of spontaneous preterm birth-associated RNA transcripts in maternal plasma. PLoS ONE. 2012;7:e34328.
52. Lipton SA, Heikkila A, Tuomisto T, Hakkinen S-K, Keski-Nisula L, Heinonen S, et al. The use of cDNA microarray to identify differentially expressed labor-associated genes within the human myometrium during labor. Am J Obstet Gynecol. 2005;193:604–13.
53. Lee GSR, Joe YS, Kim SJ, Shin JC. Cytokine-related genes and oxidation-related genes detected in preeclamptic placentas. Arch Gynecol Obstet. 2010;282:363–9.
69. Ogita K, Kimura T, Nakamura H, Koyama S, Tsujie T, Tomine M, et al. Expression of proadrenomedullin during preterm and term pregnancy. Am J Reprod Immunol. 2004;51:204–10.

70. Okamoto A, Endo H, Kalkonis B, Shinya M, Saito M, Nikaido T, et al. IGFBP1 and follistatin-like 3 genes are signficantly up-regulated in expression profiles of the IUGR placenta. Placenta. 2006;27:217-23.

71. Osei-Kumah A, Smith R, Jurisica I, Canigga I, Clifton VL. Differences in placental global gene expression in pregnancies complicated by asthma. Placenta. 2011;32:570–8.

72. Pang H-H, Kao C-C, Chang S-D, Chao A-S, Chang Y-L, Wang C-N, et al. The effects of labor on differential gene expression in parturient women, placenta, and fetuses at term pregnancy. Kuchigo. J Med Sci. 2011;27:494-502.

73. Radaelli T, Varetoffour P, Catalano P, Haugeul-de Mouzon S. Gestational diabetes induces placental genes for chronic stress and inflammatory pathways. Diabetes. 2003;52:2951–8.

74. Rehman KS, Yin S, Mayhew BA. Human myometrial adaptation to pregnancy: cDNA microarray gene expression profiling of myometrium from non-pregnant and pregnant women. Mol Hum Reprod. 2003;9:1681–700.

75. Reimer T, Kozcan D, Gerber B, Richter D, Thiessen HJ, Friese K. Microarray analysis of differentially expressed genes in placental tissue of pre-eclampsia: up-regulation of obesity-related genes. Mol Hum Reprod. 2002;8:674–80.

76. Roh CR, Budhrajya V, Kim HS, Nelson DM, Sadovsky Y. Microarray-based identification of differentially expressed genes in hypoxic human trophoblasts and in placental villi of pregnancies with growth restriction fetuses. Placenta. 2005;26:319–28.

77. Sabin J, Zhong Y, McKelvey S, Dajani NK, Andres A, Badger TM, et al. A comprehensive analysis of the human placenta transcriptome. Placenta. 2014;35:125–31.

78. Shankar R, Johnson MP, Williamson NA, Currell AW, Moses EK, et al. Molecular markers of preterm labor in the chordioidecidual. Reprod Sci. 2005;6999:309–41.

79. Sitras V, Paulssen R, Leirvik J, Vartun A, Acharya G. Placental gene expression profile in intrauterine growth restriction due to placental insufficiency. Reprod Sci. 2009;16:701–11.

80. Sitras V, Paulssen RH, Graanaa H, Leirvik J, Hanssen TA, Vartun A, et al. Differential placental gene expression in severe placenta previa. Placenta. 2009;30:424–33.

81. Sitras V, Fenton C, Paulssen R, Vartun A, Acharya G. Differences in gene expression between first and third trimester human placenta: a microarray study. PLoS ONE. 2012;7:e33294.

82. Soleymanlou N, Jurisica I, Nevo O, Ietta F, Zhang X, Zamudio S, et al. Comprehensive analysis of the human placenta transcriptome. Placenta. 2010;31:297-310.

83. Soo R, Zehnder JL, Druzin ML, Brown PO. Gene expression patterns in human placenta. Proc Natl Acad Sci U S A. 2006;103:5478-83.

84. Tashima LS, Millar NK. Genes upregulated in human fetal membranes by infection or labor. Obstet Gynecol. 1999;94(3):441-9.

85. Tattersall M, Cordeau Y, Charnock-Jones DS, Smith GCS. Expression of gastrin-releasing peptide is increased by prolonged stretch of human myometrium, and antagonists of its receptor inhibit contractility. J Physiol. 2012;590:2081–93.

86. Textoris J, Ivorra D, Ben Amara A, Sabatier F, Ménard JP, Heckenroth H, et al. Evaluation of current and New biomarkers in severe preeclampsia: a microarray approach reveals theHSG4 gene as a potential blood biomarker. PLoS ONE. 2013;8:e62638.

87. Tromp G, Kuivaniemi H, Romero R, Chaikuapongsa T, Kim YM, Kim MR, et al. Genome-wide expression profiling of fetal membranes reveals a deficient expression of proteinase inhibitor 3 in premature rupture of membranes. Am J Obstet Gynecol. 2004;191:1331-8.

88. Tsai S, Hardison NE, James AH, Motsinger-Reif AA, Bischoff SR, Thames BH, et al. Transcriptional profiling of human placentas from pregnancies complicated by preeclampsia reveals disregulation of sialic acid acetylsclere and acetylation of the sialo-glycosidase pathways. Placenta. 2011;32:175-82.

89. Uuskulla L, Männik J, Rull K, Minajeva A, Köks S, Vaas P, et al. Mid-gestational gene expression profile in placenta and link to pregnancy complications. PLoS ONE. 2012;7:e49248.

90. Várkonyi T, Nagy B, Füle T, Tarca AL, Karádi K, Schönhäbel J, et al. Microarray profiling reveals that placental transcriptomes of early-onset HELLP syndrome and preeclampsia are similar. Placenta. 2011;32(Suppl):S21–9.

91. Votava H, Dolosalova Merkerova M, Fejglova K, Vaskova A, Krejck Z, Pastorkova A, et al. Transcriptome alterations in maternal and fetal cells induced by tobacco smoke. Placenta. 2011;32:763–70.

92. Weiner CP, Mason CW, Dong Y, Buhimschi IA, Swaan PW, Buhimschi CS. Human effector/initiator gene sets that regulate myometrial contractility during term and preterm labor. Am J Obstet Gynecol. 2010;202:474.e1-6.202-8.

93. Wynn VD, Haimov-Kochman R, Paquet AC, Yang YJ, Madhusudhan MS, Gormley M, et al. Gene expression profiling of the human maternal-fetal interface reveals dramatic changes during midgestation and term. Endocrinology. 2007;148:1059–79.

94. Wynn VD, Gormley M, Paquet AC, Kjær-Sorensen K, Kramer A, Rumer KK, et al. Severe preeclampsia-related changes in gene expression at the maternal-fetal interface include sialic acid-binding immunoglobulin-like lectin-6 and pappalyasin-2. Endocrinology. 2009;150:452–62.

95. Yan YH, Yi P, Zheng YR, Yu LL, Han J, Han XM, et al. Screening for preeclampsia pathogenesis related genes. Eur Rev Med Pharmacol Sci. 2013;17:3083–94.

96. Zhang Y, Cui Y, Zhou Z, Sha J, Li Y, Liu J. Altered global gene expressions of human placenta subjected to assisted reproductive technology treatments. Placenta. 2010;31:251–8.

97. Zhao YH, Wang DP, Zhang L, Zhang F, Wang DM, Zhang WY. Genomic expression profiles of blood and placenta reveal significant immune-related pathways and categories in Chinese women with gestational diabetes mellitus. Diabet Med J Br Diabet Assoc. 2011;28:257–66.

98. Zhou R, Zhu Q, Wang Y, Ren Y, Zhang L, Zhou Y. Genome-wide oligonucleotide microarray analysis on placenta of pre-eclamptic pregnancies. Gynecol Obstet Invest. 2006;62:108–14.

99. Zhou Y, Gormley MJ, Hunkapiller NM, Kapidic M, Stolyarov Y, Feng V, et al. Reversal of gene dysregulation in cultured cytrophoblasts reveals possible causes of preeclampsia. J Clin Invest. 2013;123:2862–72.

100. Barbaux S, Gascoin-Lachambre G, Buffat C, Monnier P, Mondon F, Tonanny M-S, et al. A genome-wide approach reveals novel imprinted genes expressed in the human placenta. Epigenetics Off J DNA Methylation Soc. 2012;7:1079–90.

101. Blair JD, Yuen RKC, Lim BK, McFadden DE, von Dadelszen P, Robinson WP. Wideband DNA hypomethylation at gene enhancer regions in placentas associated with early-onset preeclampsia. Mol Hum Reprod. 2013;19:697–708.

102. Blair JD, Langlois S, McFadden DE, Robinson WP. Overlapping DNA methylation profile between placentas with trisomy 16 and early-onset preeclampsia. Placenta. 2014;35:216–22.

103. Chu T, Bunce K, Shaw P, Shridhar V, Althouse A, Hubel C, et al. Comprehensive analysis of preeclampsia-associated DNA methylation in the placenta. PLoS ONE. 2014;9:e97918.

104. Cruickshank MN, Oshlack A, Theda C, Davis PG, Martino D, Sheehan P, et al. Genome-wide approach reveals novel imprinted genes expressed in the human placenta. PLoS Genet. 2014;10:e1004798.

105. Dai Y, Saffery R, Doyle LW, Craig JM: Analysis of epigenetic changes in the placenta methylome. PNAS. 2013;110:6037–42.

106. Diem S, Saffery R, Doyle LW, Craig JM. Gestational diabetes mellitus epigenetically affects genes predominantly involved in metabolic diseases. Epigenetics Off J DNA Methylation Soc. 2013;8:935–43.

107. Schroeder DL, Blair JD, Lott P, Yu HK, Hong D, Cray F, et al. The human placenta methylome. PNAS. 2013;110:15217–22.
112. Suter M, Ma J, Harris A, Patterson L, Brown KA, Shope C, et al. Maternal tobacco use modestly alters correlated epigenome-wide placental DNA methylation and gene expression. Epigenetics Off J DNA Methylation. 2011;6(12):84–94.

113. Turan N, Ghahvsi WF, Katarí S, Couturier C, obradovic Z, sapienza C. DNA methylation differences at growth related genes correlate with birth weight: a molecular signature linked to developmental origins of adult disease? BMC Med Genomics. 2012;5:10.

114. Yuen RKC, Chen B, Blair JD, Robinson WP, Nelson DM. Hypoxia alters the epigenetic profile in cultured human placental trophoblasts. Epigenetics Off J DNA Methylation. 2013;8:192–202.

115. Choi SY, Yun J, Leu OJ, Han HS, Yeo MK, Lee MA, et al. MicroRNA expression profiles in placenta with severe preeclampsia using a PMase-based microarray. Placenta. 2013;34:799–804.

116. Elovitz MA, Brown AG, Anton L, Gistrom M, Heiser L, Bastek J. Distinct cervical microRNA profiles are present in women destined to have a preterm birth. Am J Obstet Gynecol. 2014;210:221–e1.

117. Enquobahrie DA, Abetew DF, Sorensen TK, Willoughby D, Chidambaram K, Williams MA. Placental microRNA expression in pregnancies complicated by preeclampsia. Am J Obstet Gynecol. 2012;207:18–e21.

118. Gu Y, Sun J, Ge,oeMJ, Wang Y. Differential miRNA expression profiles between the first and third trimester human placentas. Am J Physiol Endocrinol Metab. 2013;304:E836–43.

119. Guo L, Yang Q, Lu J, Li H, Ge Q, Gu W, et al. A comprehensive survey of miRNA repertoire and 3’ addition events in the placentas of patients with pre-eclampsia from high-throughput sequencing. PLoS ONE. 2011;6:e21072.

120. Hassan SS, Romero R, Pinedes B, Tarca AL, Montenegro D, Erez O, et al. MicroRNA expression profiling of the human uterine cervix after term labor and delivery. Am J Obstet Gynecol. 2010;202:80–e1.

121. Higashijima A, Miura K, Mishima H, Kinoshita A, Jo A, Abe S, et al. Characterization of placenta-specific microRNAs in fetal growth restriction pregnancy. Prenat Diagn. 2013;33:214–22.

122. Hu Y, Li P, Hao S, Liu L, Zhao J, Hou Y. Differential expression of microRNAs in Chinese patients with severe pre-eclampsia. Clin Chem Lab Med CCMFESC. 2009;47:923–9.

123. Ishibashi O, Ohkuchi A, Ali MM, Kurashina R, Luo S-S, Ishikawa T, et al. Hydroxysteroid (17β)-dehydrogenase 1 is dysregulated by mir-210 and mir-518c that are aberrantly expressed in preeclamptic placenta: a novel marker for predicting preeclampsia. Hypertension. 2012;59:65–73.

124. Luo SS, Ishibashi O, Ishikawa G, Ishikawa T, Katayama A, Mishima T, et al. Human villous trophoblasts express and secrete placenta-specific microRNAs into maternal circulation via exosomes. Biol Reprod. 2009;81:717–29.

125. Montenegro D, Romero R, Pineses BL, Tarca AL, Kim YM, Draghi C, et al. Differential expression of microRNAs with progression of gestation and inflammation in the human chorionic villi membranes. Am J Obstet Gynecol. 2007;197:259–65.

126. Montenegro D, Romero R, Kim SS, Tarca AL, Draghi C, Kusanovic JP, et al. Expression pattern of microRNAs in the chorionic villi membranes: a role for microRNAs in human pregnancy and parturition. J Pathol. 2009;213:113–21.

127. Morales-Prieto DM, Chaiwangyen W, Ospina-Prieto S, Schneider U, Williams MA. Placental microRNA expression in pregnancies complicated by preterm birth. Am J Obstet Gynecol. 2014;210:221–e1.

128. Mouillet JF, Chiu T, Nelson DM, Mishima T, Sadowsky Y. MR-205 silences miRNA expression in hypoxic primary human trophoblasts. FASEB J. 2010;24:2030–9.

129. Noack F, Ribbat-Idel J, Thorns C, Chiriac A, Axt-Fliedner R, Diedrich K, et al. miRNA expression profiling in formalin-fixed and paraffin-embedded placental tissue samples from pregnancies with severe preeclampsia. J Perinat Med. 2011;39:267–71.

130. Pinedes BL, Romero R, Montenegro D, Tarca AL, Han YM, Kim YM, et al. Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol. 2007;196:261–e1.

131. Wang W, Feng L, Zhang H, Hachisuga M, Tsukimori K, Seki H, Takeda S, et al. Gene expression profiles by microarray analysis during Matrigel-induced tube formation in a human extravillous trophoblast cell line: comparison with endothelial cells. Placenta. 2008;29:988–904.

132. Popovici RM, Betschler NK, Krause MS, Luo M, Jaukus J, Gemerye A, et al. Gene expression profiling of human endothelial-trophoblast interaction in a coculture model. Endocrinology. 2006;147:6562–75.

133. Zhu X, Han T, Sargent IL, Yin G, Yao Y. Differential expression profile of microRNAs in human placentas from preeclamptic pregnancies vs normal placentas. Am J Obstet Gynecol. 2009;200:661–e1.

134. Burleigh DW, Kendzierski CM, Choi YJ, Grindle KM, Gendrell RL, Magness RR, et al. Microarray analysis of BeWo and JEG3 trophoblast cell lines: identification of differentially expressed transcripts. Placenta. 2007;28:383–9.

135. Chen H-W, Chen JW, Tseng C-R, Li H-N, Chang S-J, Cheng Y-F, et al. Global analysis of differentially expressed genes in early gestational decidua and chorionic villi with a 9600 human cDNA microarray. Mol Hum Reprod. 2002;8:475–84.

136. Chevillard G, Derujga A, Devost D, Zingg HH, Blank V. Identification of interleukin-1 regulated genes in uterine smooth muscle cells. Reproduction. 2001;134:21–11.

137. Fukushima K, Murata M, Hachisuga M, Tsukimori K, Seki H, Takeda S, et al. Gene expression profiles by microarray analysis during Matrigel-induced tube formation in a human extravillous trophoblast cell line: comparison with endothelial cells. Placenta. 2008;29:988–904.

138. Popovici RM, Betschler NK, Krause MS, Luo M, Jaukus J, Gemerye A, et al. Gene expression profiling of human endothelial-trophoblast interaction in a coculture model. Endocrinology. 2006;147:6562–75.

139. Saloff MS, Jeng YJ, Izbam MG, Simha M, Lucon BA, Stammes SJ, et al. Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci Thousand Oaks Calif. 2011;18:781–97.

140. Brou L, Almli LM, Pearce BD, Ghat G, Drobec CO, Fontanuto S, et al. Dysregulated biomarkers induce distinct pathways in preterm birth. J Biomed Sci. 2011;18:1042–54.

141. Conde-Agudelo A, Papageorghiou A, Kennedy S, Villar J. Novel biomarkers for the prediction of the spontaneous preterm birth phenotype: a systematic review and meta-analysis: novel biomarkers to predict spontaneous preterm birth. J Biomed Sci. 2011;18:1042–54.

142. Kacerovsky M, Lenco J, Musilova I, Tambor V, Lamont R, Torloni MR, et al. Proteomic biomarkers for spontaneous preterm birth: a systematic review of the literature. Reprod Sci. 2014;2014(21):283–95.

143. Menon R, Torloni MR, Vololoini C, Torricelli M, Meraldi M, Betran AP, et al. Biomarkers of spontaneous preterm birth: an overview of the literature in the last four decades. Reprod Sci. 2011;18:1046–70.

144. Manuck TA, Esplin MS, Biggio J, Bukowski R, Parry S, Zhang H, et al. The phenotype of spontaneous preterm birth application of a clinical phenotyping tool. Am J Obstet Gynecol. 2015;212:487.e1–487.e11.

145. Hughes DA, Kircher M, He Z, Guo S, Fairbrother GL, Moreno CS, Khahtovich P, Stoneking M. Evaluating intra- and inter-individual variation in the human placental transcriptome. Genome Biol. 2015;16:54.

146. Kohler D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.

147. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, et al. Circos: an information aesthetic for comparative genomics. Genome Res. 2009;19:1639–45.

148. Wickham H. Ggplot2: Elegant Graphics for Data Analysis. New York: Springer; 2009.

Submit your next manuscript to *BioMed Central* and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at [www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)